Company Dossier · Health Care
Qiagen
- Russell 1000
What Qiagen is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Latest earnings call or results release (August 6, 2026): sentiment 0.20 on a −1 to +1 scale (mixed), confidence 0.70 of 1.Palanor Discourse
- 337 institutional managers reported a position at June 30, 2026 (−9 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 1 (1 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Qiagen yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
What the company says
In the news
Headlines that name Qiagen, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralQiagen (QGEN) Stock Surges 7.3% Amid Advanced Acquisition Talks
gurufocus.com · via Marketaux · Oct 2, 2026
- NeutralA Look at Qiagen NV (QGEN) After 3.9% Decline -- GF Value $49.92 vs Price $42.04
gurufocus.com · via Marketaux · Oct 1, 2026
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Agilent Technologies A | $7.4B | $1.3B | Jul 31, 2026 |
| AbbVie Inc. ABBV | $64.4B | $18.2B | Jun 30, 2026 |
| Abbott Laboratories ABT | $45.1B | $7.4B | Mar 31, 2026 |
| Align Technology ALGN | $4.1B | $0.6B | Jun 30, 2026 |
| Alnylam Pharmaceuticals ALNY | $3.7B | $0.5B | Dec 31, 2025 |
| Amgen AMGN | $38.1B | $10.2B | Jun 30, 2026 |
| Arrowhead Pharmaceuticals ARWR | $0.7B | −$0.1B | Jun 30, 2026 |
| Ascendis Pharma ASND | — | — | — |